Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: An emerging paradigm in diabetic nephropathy: A systematic review

European Journal of Internal Medicine

Volumn 25, Issue 2, 2014, Pages 173-176

  Mavrakanas, Thomas A ^a   Gariani, Karim ^a   Martin, Pierre Yves ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Albuminuria; Blood pressure; Diabetic nephropathy; Glomerular filtration rate; Hyperkalemia; Mineralocorticoid receptor blockade

Indexed keywords

ALBUMINURIA; BLOOD PRESSURE; DIABETIC NEPHROPATHY; GLOMERULAR FILTRATION RATE; HYPERKALEMIA; MINERALOCORTICOID RECEPTOR BLOCKADE;

ALBUMINURIA; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIABETIC NEPHROPATHIES; DRUG THERAPY, COMBINATION; GLOMERULAR FILTRATION RATE; HUMANS; HYPERKALEMIA; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RENAL INSUFFICIENCY, CHRONIC; SPIRONOLACTONE; TREATMENT OUTCOME;

EID: 84894106381     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2013.11.007     Document Type: Article

References (25)

1. B. Pitt "Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin-converting enzyme inhibitor: implications for therapy Cardiovasc Drugs Ther 9 1995 145 149
2. S.Y. Han, C.H. Kim, H.S. Kim, Y.H. Jee, H.K. Song, and M.H. Lee et al. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats J Am Soc Nephrol 17 2006 1362 1372
3. M. Taira, H. Toba, M. Murakami, I. Iga, R. Serizawa, and S. Murata et al. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats Eur J Pharmacol 589 2008 264 271
4. G. Fujisawa, K. Okada, S. Muto, N. Fujita, N. Itabashi, and E. Kusano et al. Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats Kidney Int 66 2004 1493 1502
5. C. Guo, D. Martinez-Vasquez, G.P. Mendez, M.F. Toniolo, T.M. Yao, and E.M. Oestreicher et al. Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus Endocrinology 47 2006 5363 5373
6. Y.S. Kang, G.J. Ko, M.H. Lee, H.K. Song, S.Y. Han, and K.H. Han et al. Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats Nephrol Dial Transplant 24 2009 73 84
7. T.A. Mavrakanas, A. Cheva, K. Kallaras, G. Karkavelas, and M. Mironidou-Tzouveleki Effect of ramipril alone compared to ramipril with eplerenone on diabetic nephropathy in streptozocin-induced diabetic rats Pharmacology 86 2010 85 91
8. K.J. Schjoedt, K. Rossing, T.R. Juhl, F. Boomsma, P. Rossing, and L. Tarnow et al. Beneficial impacts of spironolactone in diabetic nephropathy Kidney Int 68 2005 2829 2836
9. K. Rossing, K.J. Schjoedt, U.M. Smidt, F. Boomsma, and H.H. Parving Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy Diabetes Care 28 2005 2106 2112
10. K.J. Schjoedt, K. Rossing, T.R. Juhl, F. Boomsma, L. Tarnow, and P. Rossing et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy Kidney Int 70 2006 536 542
11. A.H. Van den Meiracker, R.G.A. Baggen, S. Pauli, A. Lindemans, A.G. Vulto, and D. Poldermans et al. Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function J Hypertens 24 2006 2285 2292
12. M. Epstein, G.H. Williams, M. Weinberger, A. Lewin, S. Krause, and R. Mukherjee et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes Clin J Am Soc Nephrol 1 2006 940 951
13. M.G. Saklayen, L.K. Gyebi, J. Tasosa, and J. Yap Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial J Investig Med 56 2008 714 719
14. U.F. Mehdi, B. Adams-Huet, P. Raskin, G.L. Vega, and R.D. Toto Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy J Am Soc Nephrol 20 2009 2641 2650
15. S.E. Nielsen, F. Persson, E. Frandsen, T. Sugaya, G. Hess, and D. Zdunek et al. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study Diabet Med 29 2012 e184 e190
16. J.E. Heeg, P.E. de Jong, G.K. van der Hem, and D. de Zeeuw Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril Kidney Int 36 1989 272 279
17. N.K. Hollenberg Aldosterone in the development and progression of renal injury Kidney Int 66 2004 1 9
18. J.P. Bertocchio, D.G. Warnock, and F. Jaisser Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease Kidney Int 79 2011 1051 1060
19. A. Sato, K. Hayashi, M. Naruse, and T. Saruta Effectiveness of aldosterone blockade in patients with diabetic nephropathy Hypertension 41 2003 64 68
20. W. Linz, G. Wiemer, P. Gohlke, T. Unger, and B.A. Scholkens Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors Pharmacol Rev 47 1995 25 49
21. K.F. Schulz, I. Chalmers, R.J. Hayes, and D.G. Altman Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials JAMA 273 1995 408 412
22. D. Moher, B. Pham, A. Jones, D.J. Cook, A.R. Jadad, and M. Moher et al. Does quality of reports of randomized trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 352 1998 609 613
23. ONTARGET Investigators, S. Yusuf, K.K. Teo, J. Pogue, J. Pogue, and L. Dyal et al. Telmisartan, ramipril, or both in patients at high risk for vascular events N Engl J Med 358 2008 1547 1559
24. NOVARTIS Media Release: NOVARTIS announces termination of ALTITUDE study Assessed at http://www.novartis.com/downloads/newsroom/product-related-info- center/Altitude-Rasilez-Tekturna-press-release.pdf [on 04.22.2013]
25. L.C. Reardon, and D.S. Macpherson Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry? Arch Intern Med 158 1998 26 32